TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/04/2025
Back to search
Official data from USPTO
ATAC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
54
Latest update
02/04/2025
Trademark type
Word
Nice classes
5, 42, 44
Filing date
05/21/2019
Registration date
11/01/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/01/2022
Last transaction
02/04/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
Ladenburg, DE
Examiner
STURMAN, MELISSA M
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Heidelberg Pharma Research GmbH
Representatives
Todd A. Sullivan Hayes Soloway P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationsanti-cancer and immunosuppression preparations; pharmaceuticalsanti-cancer and immunosuppression preparations; chemico-pharmaceutical preparationschemical preparations for medical purposes for the treatment of cancer and immunosuppression; pharmaceutical preparations and substancespharmaceutical products for the treatment of cancer and immunosuppression; pharmaceutical preparationsanti-cancer preparations for veterinary use; chemical preparations for pharmaceutical purposeschemical preparations for the treatment of cancer and immunosupression; pharmaceutical preparations for human usepharmaceutical preparations for human use in the treatment of cancer and immnunosupression; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for use in oncology; diagnostic preparations for medical purposes; diagnostic agents for pharmaceutical use; diagnostic agents for medical use; diagnostic preparations for veterinary purposes; clinical diagnostic reagents for medical use; diagnostic chemical reagents for medical use; anti-cancer drugsanti-cancer preparations; pharmaceutical compounds for treating cancer and immunosuppression; anti-cancer preparations; anti-cancer preparations of chemical origin; biopharmaceuticalsanti-cancer preparations for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics; antibodies being pharmaceutical preparations for the treatment of cancer and immunosuppression; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression with agents including amatoxin
Class 42
Pharmaceutical research services; medical and pharmacological research services; pharmaceutical products development; development of pharmaceutical preparations and medicines; consultancy relating to pharmaceutical research and development; provision of medical research services; scientific research; medical research; biomedical research services; research relating to biotechnology; research on the subject of pharmaceuticals; consultancy relating to research in the field of pharmacogenetics; research and development in the pharmaceutical and biotechnology fields; research and development in the field of diagnostic preparations; research and development in the field of biotechnology; pharmaceutical research and development for the pharmaceutical industry; research and development services in the field of antibody technology; research and development services in the field of antibodies; scientific laboratory services relating to the production of monoclonal antibodies; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression
Class 44
Pharmaceutical advice; pharmaceutical consultation services; consultancy and information services relating to pharmaceutical products; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression
Publications
History of USPTO decisions and trademark events.
54 publications found
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
02/04/2025
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
02/04/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/04/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/04/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/04/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/04/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/01/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
11/01/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/16/2022
PUBO
PUBLISHED FOR OPPOSITION
08/16/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/27/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/08/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/06/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/05/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
07/05/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/13/2022
GNFR
FINAL REFUSAL E-MAILED
01/13/2022
CNFR
FINAL REFUSAL WRITTEN
01/13/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/29/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/29/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
11/15/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
10/05/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
10/05/2021
CNSI
SUSPENSION INQUIRY WRITTEN
10/05/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
08/25/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/05/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/05/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/05/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/05/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/05/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
12/07/2020
GNSL
LETTER OF SUSPENSION E-MAILED
12/07/2020
CNSL
SUSPENSION LETTER WRITTEN
12/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/04/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
11/25/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/23/2020
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/23/2020
CNSI
SUSPENSION INQUIRY WRITTEN
11/23/2020
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
11/02/2020
ALIE
ASSIGNED TO LIE
11/02/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/26/2020
GNSL
LETTER OF SUSPENSION E-MAILED
02/26/2020
CNSL
SUSPENSION LETTER WRITTEN
02/26/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/11/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/10/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/10/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/09/2019
GNRT
NON-FINAL ACTION E-MAILED
08/09/2019
CNRT
NON-FINAL ACTION WRITTEN
08/09/2019
DOCK
ASSIGNED TO EXAMINER
08/08/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/05/2019
NWAP
NEW APPLICATION ENTERED
05/24/2019
Continuous trademark protection
Get notified about every new filing that threatens ATAC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.